Szabo Yamashita Thomas, Shirali Aditya S, Meas Salyna, Sarli Vanessa, Clemente-Gutierrez Uriel E, Chiang Yi-Ju, Silva-Figueroa Angelica, Vodopivec Danica M, Williams Michelle, Fisher Sarah B, Graham Paul H, Grubbs Elizabeth G, Lucci Anthony, Busaidy Naifa, Perrier Nancy D
MD Anderson Cancer Center, Department of Surgical Oncology, Houston, TX.
MD Anderson Cancer Center, Breast Surgical Oncology, Houston, TX.
Surgery. 2024 Jan;175(1):193-198. doi: 10.1016/j.surg.2023.07.043. Epub 2023 Nov 22.
Parathyroid carcinoma is a rare malignancy with high recurrence rates. Liquid biopsy is a stratifying tool in disease recurrence/progression in other malignant processes. This study sought to assess the feasibility and application of liquid biopsy in parathyroid carcinoma and its impact on surveillance.
Retrospective review of a prospectively maintained database of adults treated for parathyroid carcinoma at a tertiary care center (2017-2023). Demographics, clinical characteristics, and laboratory variables were collected. Circulating cell-free deoxyribonucleic acid enrichment and circulating tumor cell enumeration were obtained from serial blood samples.
A total of 25 patients were identified-64% were male patients, with a median age of 56 years (interquartile range 45-63). Fifty blood samples were collected postoperatively. At first, circulating tumor cell enumeration, 56% (14/25) of patients had no evidence of disease, and 32% (8/25) had distant metastasis. Median follow-up was 53 months (interquartile range 23-107). At the last follow-up, 40% (10/25) of patients were found to have distant metastasis. Serial circulating tumor cell enumeration was performed in 52% of patients, median highest circulating tumor cell was (interquartile range 1-22). Circulating cell-free deoxyribonucleic acid was assessed in 64% of patients (16/25). There was no difference in circulating tumor cells or circulating cell-free deoxyribonucleic acid between those with distant metastasis and those without distant metastasis. The most common mutation identified was TP53, present in 88% of circulating cell-free deoxyribonucleic acid samples with a mutation. Circulating cell-free deoxyribonucleic acid and parathyroid hormone levels were not found to have any association (r = -0.27, P = .39), but parathyroid hormone and circulating tumor cell had a linear relationship (r = 0.76, P < .001).
Liquid biopsy appears to be a feasible tool in parathyroid carcinoma surveillance. The relationship between circulating cell-free deoxyribonucleic acid and parathyroid hormone levels remains unclear, and the association between circulating tumor cell enumeration and parathyroid hormone levels may be impactful. The finding that TP53 mutation is more prevalent in patients with distant metastasis may impact further management.
甲状旁腺癌是一种罕见的恶性肿瘤,复发率高。液体活检是其他恶性疾病复发/进展的分层工具。本研究旨在评估液体活检在甲状旁腺癌中的可行性和应用及其对监测的影响。
回顾性分析一家三级医疗中心(2017 - 2023年)前瞻性维护的接受甲状旁腺癌治疗的成人数据库。收集人口统计学、临床特征和实验室变量。从系列血样中获取循环游离脱氧核糖核酸富集和循环肿瘤细胞计数。
共纳入25例患者,64%为男性患者,中位年龄56岁(四分位间距45 - 63岁)。术后采集了50份血样。最初,循环肿瘤细胞计数显示,56%(14/25)的患者无疾病证据,32%(8/25)有远处转移。中位随访时间为53个月(四分位间距23 - 107个月)。在最后一次随访时,40%(10/25)的患者有远处转移。52%的患者进行了系列循环肿瘤细胞计数,中位最高循环肿瘤细胞数为(四分位间距1 - 22)。64%(16/25)的患者评估了循环游离脱氧核糖核酸。有远处转移和无远处转移患者的循环肿瘤细胞或循环游离脱氧核糖核酸无差异。鉴定出的最常见突变是TP53,在88%有突变的循环游离脱氧核糖核酸样本中存在。未发现循环游离脱氧核糖核酸与甲状旁腺激素水平有任何关联(r = -0.27,P = 0.39),但甲状旁腺激素与循环肿瘤细胞有线性关系(r = 0.76,P < 0.001)。
液体活检似乎是甲状旁腺癌监测的可行工具。循环游离脱氧核糖核酸与甲状旁腺激素水平之间的关系仍不清楚,循环肿瘤细胞计数与甲状旁腺激素水平之间的关联可能有影响。TP53突变在有远处转移患者中更普遍这一发现可能影响进一步治疗。